INTELLIGENT BIO SOLUTIONS INC. Financing Cash Flow
INTELLIGENT BIO SOLUTIONS INC. (INBS) reported Financing Cash Flow of $14.98 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-19
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $311.99K, a 48.17% decline year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $10.44M, a 214.27% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $674.65K, a 6.79% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.56M, a 8282.01% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for fiscal 2026 was $14.98M, a 225.89% increase from fiscal 2025.
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for fiscal 2025 was $4.60M, a 68.42% decline from fiscal 2024.
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for fiscal 2024 was $14.56M, a 914.44% increase from fiscal 2023.
- INTELLIGENT BIO SOLUTIONS INC. net cash provided by (used in) financing activities for fiscal 2023 was $1.44M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $311.99K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $10.75M derived: sum of 2 quarters · filed 2026-08-19 | $11.43M derived: sum of 3 quarters · filed 2026-08-19 | $14.98M 10-K · filed 2026-08-19 |
| 2026-03-31 | $10.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $11.11M derived: sum of 2 quarters · filed 2026-05-13 | $14.67M 10-Q · filed 2026-05-13 | $15.27M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $674.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $4.23M 10-Q · filed 2026-02-12 | $4.83M derived: sum of 3 quarters · filed 2026-08-19 | $8.16M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | $3.56M 10-Q · filed 2025-11-12 | $4.16M derived: sum of 2 quarters · filed 2026-08-19 | $7.48M derived: sum of 3 quarters · filed 2026-08-19 | $8.11M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $602.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $3.92M derived: sum of 2 quarters · filed 2026-08-19 | $4.56M derived: sum of 3 quarters · filed 2026-08-19 | $4.60M 10-K · filed 2026-08-19 |
| 2025-03-31 | $3.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $3.95M derived: sum of 2 quarters · filed 2026-05-13 | $4.00M 10-Q · filed 2026-05-13 | $4.00M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $631.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $674.19K 10-Q · filed 2026-02-12 | $679.51K derived: sum of 3 quarters · filed 2026-02-12 | $11.45M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $42.45K 10-Q · filed 2025-11-12 | $47.76K derived: sum of 2 quarters · filed 2025-11-12 | $10.82M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $5.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-15 | $10.77M derived: sum of 2 quarters · filed 2025-08-15 | $14.56M 10-K · filed 2025-08-15 | |
| 2024-03-31 | $10.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $14.56M 10-Q · filed 2025-05-13 | ||
| 2023-12-31 | $3.79M 10-Q · filed 2025-02-13 | |||
| 2023-06-30 | $46.11K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $1.76M derived: sum of 2 quarters · filed 2024-09-18 | $1.44M 10-K · filed 2024-09-18 | |
| 2023-03-31 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-08 | $1.39M 10-Q · filed 2024-05-08 | ||
| 2022-12-31 | -$328.41K 10-Q · filed 2024-02-09 | |||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-22 | $498.10K derived: sum of 2 quarters · filed 2022-09-22 | $20.11M derived: sum of 3 quarters · filed 2022-09-22 | $23.40M 10-K · filed 2022-09-22 |
| 2021-03-31 | $498.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $20.11M derived: sum of 2 quarters · filed 2022-05-16 | $23.40M 10-Q · filed 2022-05-16 | $23.60M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $19.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-11 | $22.90M 10-Q · filed 2022-02-11 | $23.11M derived: sum of 3 quarters · filed 2022-02-11 | $23.11M derived: sum of 4 quarters · filed 2022-02-11 |
| 2020-09-30 | $3.29M 10-Q · filed 2021-11-12 | $3.50M derived: sum of 2 quarters · filed 2021-11-12 | $3.50M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $201.51K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-16 | $201.51K derived: sum of 2 quarters · filed 2021-09-16 | $733.86K 10-K · filed 2021-09-16 | |
| 2020-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | $532.35K 10-Q · filed 2021-05-13 | ||
| 2019-12-31 | $532.35K 10-Q · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |